The optimal treatment for in-stent restenosis (ISR) of both bare-metal stent (BMS) and drug-eluting stent (DES) is currently unclear. The aim of this meta-analysis was to assess the role of drug-eluting balloon (DEB) as an optional treatment for ISR. We searched PubMed, MEDLINE, EMBASE, BIOS, and Web of Science from 2005 to July 2014. Eight studies, enrolling 1413 patients were included. Main end points were late lumen loss (LLL), binary in-segment restenosis (BR), major adverse cardiac events (MACEs), target lesion revascularization (TLR), death, myocardial infarction (MI), and stent thrombosis (ST). When compared to plain old balloon angioplasty (POBA), DEB treatment significantly reduced the risk of MACE (risk rato [RR] 0.37, P < .01), death (RR 0.44, P = .04), TLR (RR 0.27, P < .01), BR (RR [95% CI]: 0.23[0.12 to 0.43], P < .01) and associated with better outcomes of LLL ( 0.50 [ 0.65 to 0.35] mm, P < .01). However, the differences were not significant between DEB treatment and DES treatment in all primary and secondary end points. The DEB was a better option to treat ISR when compared to POBA. However, it had similar effects as DES.
HendersonRATimmisAD. Almanac 2011: Stable coronary artery disease. An editorial overview of selected research that has driven recent advances in clinical cardiology [in Italian]. G Ital Cardiol (Rome). 2012;13(4):244–253.
2.
SchellerBSpeckUAbramjukCBernhardtUBohmMNickenigG. Paclitaxel balloon coating, a novel method for prevention and therapy of restenosis. Circulation. 2004;110(7):810–814.
3.
SpeckUSchellerBAbramjukC. Neointima inhibition: comparison of effectiveness of non-stent-based local drug delivery and a drug-eluting stent in porcine coronary arteries. Radiology. 2006;240(2):411–418.
4.
CremersBSpeckUKaufelsN. Drug-eluting balloon: very short-term exposure and overlapping. Thromb Haemost. 2009;101(1):201–206.
5.
HabaraSIwabuchiMInoueN. A multicenter randomized comparison of paclitaxel-coated balloon catheter with conventional balloon angioplasty in patients with bare-metal stent restenosis and drug-eluting stent restenosis. Am Heart J. 2013;166(3):527–533.
6.
AlfonsoFPérez-VizcaynoMJCárdenasA. A randomized comparison of drug-eluting balloon versus everolimus-eluting stent in patients with bare-metal stent–in-stent restenosis. J Am Coll Cardiol. 2014;63(14):1378–1386.
7.
XuBGaoRWangJ. A prospective, multicenter, randomized trial of paclitaxel-coated balloon versus paclitaxel-eluting stent for the treatment of drug-eluting stent in-stent restenosis: results from the PEPCAD China ISR trial. JACC Cardiovasc Interv. 2014;7(2):204–211.
8.
ByrneRANeumannFMehilliJ. Paclitaxel-eluting balloons, paclitaxel-eluting stents, and balloon angioplasty in patients with restenosis after implantation of a drug-eluting stent (ISAR-DESIRE 3): a randomised, open-label trial. Lancet. 2013;381(9865):461–467.
9.
SchellerBCleverYPKelschB. Long-term follow-up after treatment of coronary in-stent restenosis with a paclitaxel-coated balloon catheter. JACC Cardiovasc Intervent. 2012;5(3):323–330.
10.
RittgerHBrachmannJSinhaA. A randomized, multicenter, single-blinded trial comparing paclitaxel-coated balloon angioplasty with plain balloon angioplasty in drug-eluting stent restenosis. J Am Coll Cardiol. 2012;59(15):1377–1382.
11.
HabaraSMitsudoKKadotaK. Effectiveness of paclitaxel-eluting balloon catheter in patients with sirolimus-eluting stent restenosis. JACC Cardiovasc Intervent. 2011;4(2):149–154.
12.
UnverdorbenMVallbrachtCCremersB. Paclitaxel-coated balloon catheter versus paclitaxel-coated stent for the treatment of coronary in-stent restenosis. Circulation. 2009;119(23):2986–2994.
13.
HigginsJPTAltmanDGGotzschePC. The Cochrane Collaboration’s tool for assessing risk of bias in randomised trials. BMJ. 2011;343(2):d5928.
14.
MoherDLiberatiATetzlaffJAltmanDG. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA Statement. Open Med. 2009;3(3):e123–e130.
15.
IndermuehleABahlRLanskyAJ. Drug-eluting balloon angioplasty for in-stent restenosis: a systematic review and meta-analysis of randomised controlled trials. Heart. 2013;99(5):327–333.
16.
PalmeriniTBiondi-ZoccaiGDellaRD. Stent thrombosis with drug-eluting and bare-metal stents: evidence from a comprehensive network meta-analysis. Lancet. 2012;379(9824):1393–1402.
17.
AlfonsoFFernandezC. Second-generation drug-eluting stents. Moving the field forward. J Am Coll Cardiol. 2011;58(1):26–29.
18.
AlfonsoF. Treatment of drug-eluting stent restenosis the new pilgrimage: quo vadis?J Am Coll Cardiol. 2010;55(24):2717–2720.
19.
AlfonsoFByrneRARiveroFKastratiA. Current treatment of in-stent restenosis. J Am Coll Cardiol. 2014;63(24):2659–2673.
20.
AlfonsoFPerez-VizcaynoMJGomez-RecioM. Implications of the “watermelon seeding” phenomenon during coronary interventions for in-stent restenosis. Catheter Cardiovasc Interv. 2005;66(4):521–527.
21.
AlfonsoFGarciaPFleitesH. Repeat stenting for the prevention of the early lumen loss phenomenon in patients with in-stent restenosis. Angiographic and intravascular ultrasound findings of a randomized study. Am Heart J. 2005;149(2):e1–e8.
22.
AlfonsoFPerez-VizcaynoMJHernandezR. A randomized comparison of sirolimus-eluting stent with balloon angioplasty in patients with in-stent restenosis: results of the Restenosis Intrastent: Balloon Angioplasty Versus Elective Sirolimus-Eluting Stenting (RIBS-II) trial. J Am Coll Cardiol. 2006;47(11):2152–2160.
23.
DibraAKastratiAAlfonsoF. Effectiveness of drug-eluting stents in patients with bare-metal in-stent restenosis: meta-analysis of randomized trials. J Am Coll Cardiol. 2007;49(5):616–623.
24.
StoneGWEllisSGO’ShaughnessyCD. Paclitaxel-eluting stents vs vascular brachytherapy for in-stent restenosis within bare-metal stents: the TAXUS V ISR randomized trial. JAMA. 2006;295(11):1253–1263.
25.
KastratiASch MigAMehilliJ. Sirolimus-eluting stent or paclitaxel-eluting stent vs balloon angioplasty for prevention of recurrences in patients with coronary in-stent restenosis: a randomized controlled trial. JAMA. 2005;293(2):165.
26.
AlfonsoFSchellerB. Management of recurrent in-stent restenosis: onion skin full metal jacket?EuroIntervention. 2013;9(7):781–785.
27.
AlfonsoFPerez-VizcaynoMJCardenasA. A prospective randomized trial of drug-eluting balloons versus everolimus-eluting stents in patients with in-stent restenosis of drug-eluting stents: the RIBS IV randomized clinical trial. J Am Coll Cardiol. 2015;66(1):23–33.
28.
AlliOOTeirsteinPSSatlerL. Five-year follow-up of the Sirolimus-Eluting Stents vs Vascular Brachytherapy for Bare Metal In-Stent Restenosis (SISR) trial. Am Heart J. 2012;163(3):438–445.
29.
De LabriolleAPakalaRBonelloLLemesleGScheinowitzMWaksmanR. Paclitaxel-eluting balloon: from bench to bed. Catheter Cardiovasc Interv. 2009;73(5):643–652.
30.
SpeckUCremersBKelschB. Do pharmacokinetics explain persistent restenosis inhibition by a single dose of paclitaxel?Circ Cardiovasc Interv. 2012;5(3):392–400.
31.
CremersBMilewskiKCleverYPAboodiMSBiedermannMThimT. Long-term effects on vascular healing of bare metal stents delivered via paclitaxel-coated balloons in the porcine model of restenosis. Catheter Cardiovasc Interv. 2012;80(4):603–610.
